Difficulty: Medium
Average Score: 80%
Practice
A 58-year-old man who is a smoker with chronic obstructive pulmonary disease (COPD) presents to the emergency department (ED) with shortness of breath and a productive cough. This is the fourth time this year he has come to the ED because of COPD exacerbation. After this hospital stay, his primary care physician prescribes roflumilast in hopes of decreasing his ED visits for COPD exacerbation. What is roflumilastÔÇÖs mechanism of action?
Correct answer
D
Rationale
Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor, making option D the correct answer. PDE4 inhibitors like roflumilast work by blocking the enzyme PDE4, which leads to increased intracellular levels of cyclic adenosine monophosphate (cAMP). This increase in cAMP helps reduce inflammation in the lungs, making it an effective treatment for COPD exacerbations.
Option A is incorrect because blocking arachidonic acid production is not the mechanism of action of roflumilast. Arachidonic acid is involved in the inflammatory process but is not directly targeted by roflumilast.
Option B, bronchodilation, is not the primary mechanism of action of roflumilast. While bronchodilation is a common treatment approach for COPD, roflumilast specifically targets inflammation rather than directly causing bronchodilation.
Option C, inhibition of leukocyte chemotaxis by interfering with microtubules, is also incorrect. This mechanism of action does not apply to roflumilast but rather to other medications with different modes of action in the treatment of inflammatory conditions.
In an educational context, understanding the mechanism of action of medications is crucial for healthcare providers to make informed decisions about treatment options for their patients. Knowing how roflumilast works as a PDE4 inhibitor helps in prescribing it appropriately for patients with COPD, like the 58-year-old man in the scenario, to improve their outcomes and reduce exacerbations.
Option A is incorrect because blocking arachidonic acid production is not the mechanism of action of roflumilast. Arachidonic acid is involved in the inflammatory process but is not directly targeted by roflumilast.
Option B, bronchodilation, is not the primary mechanism of action of roflumilast. While bronchodilation is a common treatment approach for COPD, roflumilast specifically targets inflammation rather than directly causing bronchodilation.
Option C, inhibition of leukocyte chemotaxis by interfering with microtubules, is also incorrect. This mechanism of action does not apply to roflumilast but rather to other medications with different modes of action in the treatment of inflammatory conditions.
In an educational context, understanding the mechanism of action of medications is crucial for healthcare providers to make informed decisions about treatment options for their patients. Knowing how roflumilast works as a PDE4 inhibitor helps in prescribing it appropriately for patients with COPD, like the 58-year-old man in the scenario, to improve their outcomes and reduce exacerbations.